The safety of rosiglitazone in the treatment of type 2 diabetes
- PMID: 18759710
- DOI: 10.1517/14740338.7.5.579
The safety of rosiglitazone in the treatment of type 2 diabetes
Abstract
Background: Cardiovascular disease is the leading cause of mortality among adults with Type 2 diabetes. The thiazolidinediones including rosiglitazone are approved for the treatment of Type 2 diabetes on the basis of their ability to lower blood sugar and surrogate markers of cardiovascular disease.
Objectives: To ascertain the cardiovascular, skeletal and hematologic safety profile of rosiglitazone.
Methods: Synthesis of evidence from recent trials, systematic reviews, meta-analysis, regulatory documents and clinical trials registries of manufacturers.
Conclusion: Rosiglitazone increases the risk of heart failure, myocardial infarction and fractures (in women) with Type 2 diabetes.
Similar articles
-
Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.JAMA. 2007 Sep 12;298(10):1189-95. doi: 10.1001/jama.298.10.1189. JAMA. 2007. PMID: 17848653
-
Type 2 diabetes, thiazolidinediones, and cardiovascular risk.Br J Gen Pract. 2009 Jul;59(564):520-4. doi: 10.3399/bjgp09X453440. Br J Gen Pract. 2009. PMID: 19567003 Free PMC article.
-
Safety and efficacy of rosiglitazone in the elderly diabetic patient.Vasc Health Risk Manag. 2009;5(1):389-95. doi: 10.2147/vhrm.s4053. Vasc Health Risk Manag. 2009. PMID: 19475776 Free PMC article. Review.
-
[Uncertainly after publications on glitazones. Elevated myocardial infarction risk is not a class effect].MMW Fortschr Med. 2007 Dec 6;149(49-50):49-50. doi: 10.1007/BF03365260. MMW Fortschr Med. 2007. PMID: 18236983 German. No abstract available.
-
The current role of thiazolidinediones in diabetes management.Arch Toxicol. 2016 Aug;90(8):1861-81. doi: 10.1007/s00204-016-1737-4. Epub 2016 May 10. Arch Toxicol. 2016. PMID: 27165418 Review.
Cited by
-
Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione.J Biol Chem. 2012 Jul 6;287(28):23537-48. doi: 10.1074/jbc.M112.363960. Epub 2012 May 23. J Biol Chem. 2012. PMID: 22621923 Free PMC article.
-
Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.Circulation. 2013 Aug 20;128(8):785-94. doi: 10.1161/CIRCULATIONAHA.112.000678. Epub 2013 Jul 15. Circulation. 2013. PMID: 23857320 Free PMC article. Clinical Trial.
-
Risk of fractures with glitazones: a critical review of the evidence to date.Drug Saf. 2009;32(7):539-47. doi: 10.2165/00002018-200932070-00001. Drug Saf. 2009. PMID: 19530741 Review.
-
Diabetes mellitus: new challenges and innovative therapies.EPMA J. 2010 Mar;1(1):138-63. doi: 10.1007/s13167-010-0010-9. Epub 2010 Mar 13. EPMA J. 2010. PMID: 23199048 Free PMC article.
-
Risk management and outcomes of adverse events to pioglitazone in primary care in the UK: an observational study.Drug Saf. 2009;32(3):229-37. doi: 10.2165/00002018-200932030-00005. Drug Saf. 2009. PMID: 19338380
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
